Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
about
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitroIdentification of direct protein targets of small moleculesDirect non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapyOxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenaseCyclooxygenase-2 in epilepsy.Current perspectives in NSAID-induced gastropathyThe Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review ArticleReduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritisHow do aspirin and company work? Cyclooxygenases--point of attack of nonsteroidal antirheumaticsSuppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancerA three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitorsOpposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin IIThe anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2Synergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysisInhibition mechanism of the intracellular transporter Ca2+-pump from sarco-endoplasmic reticulum by the antitumor agent dimethyl-celecoxibChemical composition of Nigella sativa Linn: Part 2 Recent advancesThe effect of celecoxib, a cyclooxygenase-2 inhibitor on noise- induced hearing loss.Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular functionEfficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells.Diverse methyl sulfone-containing benzo[b]thiophene library via iodocyclization and palladium-catalyzed coupling.4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2).Synthesis of Novel Pyrazoles via [2+3]-Dipolar Cycloaddition Using Alkyne Surrogates.Radiochemistry on electrodes: Synthesis of an 18F-labelled and in vivo stable COX-2 inhibitor.Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation.Analysis of Gene Expression in Human Dermal Fibroblasts Treated with Senescence-Modulating COX Inhibitors.Anti-inflammatory drugs: a hope for Alzheimer's disease?Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.Phospholipase A2 regulates eicosanoid class switching during inflammasome activationTransgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry.An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals.C-H bonds as ubiquitous functionality: a general approach to complex arylated pyrazoles via sequential regioselective C-arylation and N-alkylation enabled by SEM-group transposition.Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib.Antimicrobial screening and one-pot synthesis of 4-(substituted-anilinomethyl)-3-(2-naphthyl)-1-phenyl-1H-pyrazole derivativesDesign of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.The role of potassium channel activation in celecoxib-induced analgesic action.BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs.
P2860
Q21245723-B934CFDC-807D-4056-A278-63DD421401CFQ21558640-757003E4-76DC-4F12-8D49-C25158B2A4E3Q24653348-8BB187A6-51F3-451D-B077-3A12B37CAF89Q24682914-DBACC8E2-5DA9-41B0-B731-842F7DC26F9CQ26827095-53CDBA4F-D5FC-45C5-AA71-515E25995243Q26827673-5383D506-7F4D-4FBA-9047-DF8284BDEF8FQ28075382-C080D50B-9F02-40DC-BE86-BC399DA485D6Q28182192-A4944E18-BEC5-4AA0-9A06-69A3C6D3C393Q28192866-A5E61A96-02DE-484B-B4C8-06F78033C0A5Q28195124-7DC88045-B2F7-498C-999F-3D756230A292Q28344403-3C76D137-2972-43DA-85D3-1864881122FEQ28508911-861126A2-E6D7-488B-87EC-8FB3DF2BF8A9Q28533258-15764A86-71C3-45AE-99CD-66CF95F01288Q28534142-2F2A0989-CEE3-4457-B88D-21F1B0D19F4CQ28540515-975DBDDA-FB01-4163-932A-7D9ED04C7650Q28833205-75C70F9B-E0F1-4F76-BA3D-610AAC822D86Q30452689-2A380525-6EC2-425C-99D6-7D5B8F2DAFADQ30477135-0C4836AD-60BE-4DCA-A777-E289559D6CF1Q32045021-47ACA2B1-595C-48CC-BE16-9E05C85533D1Q33443011-BA1020EC-8856-48EC-A02C-747CEE73B857Q33522431-BE808523-2142-4F9D-8763-0DEF372B4D55Q33610651-40DF0EAD-177A-4D4A-908E-A98AC86482BDQ33622911-EFA63020-DDCB-4C15-A6DC-E6116AB9CD2CQ33626578-34EB7916-6A2C-403B-BDF6-D911E4AB2F7CQ33814940-3CB8279B-AB47-4344-B4AC-05CD93207FE3Q33819277-09665F92-F7AD-47DC-BCAF-29DCAD486E62Q34074779-5B171085-5016-4559-9ECB-690CE1CF7960Q34082384-7718670C-C62E-4123-BF41-F6CE736CA15EQ34119511-BAB050F7-6CAD-4F36-847C-F17988863D13Q34144445-621E8F77-E708-4573-BE44-7D22138732D8Q34156486-27D14577-9195-4E47-A110-21CF8F71DB90Q34158845-CA34FB37-AD63-44AE-9B8E-E0EC30270F55Q34190368-3B8FD232-B106-4148-9C56-32829C026C16Q34198198-DA990B38-3102-4ADD-BB14-EFCF47C40A74Q34240778-0EE2AEA9-CA7E-447B-8E07-6C92D345A74DQ34417632-F88B572B-092B-4A45-B6D0-5D43CFB36DB1Q34508137-028FD7C1-194E-41CC-8D6B-40DF1C9494D1Q34519695-91CE9E7D-DF3F-4058-8F1C-AC1D2E180221Q34566035-98F33776-B5C5-44E5-8D0D-71D480EBBB02Q34581082-2D4C8AC6-A550-4A00-BBB8-3BB1689C96C7
P2860
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
description
1997 nî lūn-bûn
@nan
1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@ast
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@en
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@nl
type
label
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@ast
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@en
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@nl
prefLabel
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@ast
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@en
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@nl
P2093
P356
P1476
Synthesis and biological evalu ...... onamide (SC-58635, celecoxib).
@en
P2093
AndersonGD
Bertenshaw SR
Cogburn JN
Collins PW
Graneto MJ
Gregory SA
Isakson PC
P304
P356
10.1021/JM960803Q
P407
P577
1997-04-01T00:00:00Z